Search Results - "Beygi, Hooman"

Pharmacokinetics, metabolism and safety of deuterated L‐DOPA (SD‐1077)/carbidopa compared to L‐DOPA/carbidopa following single oral dose administration in healthy subjects by Schneider, Frank, Erisson, Lavi, Beygi, Hooman, Bradbury, Margaret, Cohen‐Barak, Orit, Grachev, Igor D., Guzy, Serge, Loupe, Pippa S., Levi, Micha, McDonald, Mirna, Savola, Juha‐Matti, Papapetropoulos, Spyros, Tracewell, William G., Velinova, Maria, Spiegelstein, Ofer

“…Aims SD‐1077, a selectively deuterated precursor of dopamine (DA) structurally related to L‐3,4‐dihydroxyphenylalanine (L‐DOPA), is under development for…”
Get full text

Long-term efficacy, safety, and tolerability of three-times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 5-year results of the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study (P6.378) by Alexander, Jessica, Beygi, Hooman, Feldman, Peter, Ashtamker, Natalia

“…Abstract only…”
Get full text

The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis by Nordstrom, Beth L., Knopf, Kevin B., Teltsch, Dana Y., Engle, Robert, Beygi, Hooman, Sterchele, James A.

“…Abstract This retrospective study compared adverse-event rates in patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL), with and…”
Get full text

Retrospective safety assessment of bendamustine in patients with renal impairment by Nordstrom, Beth L, Knopf, Kevin B., Teltsch, Dana, Engle, Robert, Beygi, Hooman, Sterchele, James A.

“…Abstract only e13081 Background: Patients with non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are at risk for renal impairment as the…”
Get full text

Demographics, Treatment Patterns, Safety, and Real-World Effectiveness in Patients ≥70 Years of Age with Chronic Lymphocytic Leukemia Receiving Bendamustine with or without Rituximab by Kolibaba, Kathryn S., Joshi, Avani D., Sterchele, James A., Forsyth, Michael, Alwon, Erin, Beygi, Hooman, Kennealey, Gerard T.

“…Abstract 3914 Bendamustine is a unique, well-established alkylating agent with multifaceted actions leading to cancer cell death in several hematologic…”
Get full text

Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study by Kolibaba, Kathryn S., Sterchele, James A., Joshi, Avani D., Forsyth, Michael, Alwon, Erin, Beygi, Hooman, Kennealey, Gerard T.

“…Objectives: Bendamustine is a unique cytotoxic agent active against various human malignancies, including chronic lymphocytic leukemia (CLL). In vitro studies…”
Get full text